Vivos Therapeutics

General Information

We are a revenue stage medical technology company focused on the development and commercialization of a highly differentiated technology offering a clinically effective non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). We offer novel and proprietary alternatives for treating mild-to-moderate OSA as well as certain craniofacial and anatomical anomalies known to be associated with OSA. We believe our products and technology represent a significant improvement in the treatment of mild-to-moderate OSA versus other treatments such as CPAP.

(Note: The Vivos Therapeutics IPO was slightly upsized, with 3.5 million shares priced, up from 3.3 million shares in the prospectus. The IPO price was $6 a share, in the middle of the deal’s $5-to-$7 price range.)

Employees: 92
Founded: 2016
Contact Information
Address 9137 Ridgeline Boulevard, Suite 135, Highlands Ranch, CO 80129, US
Phone Number (866) 908-4867
Web Address
View Prospectus: Vivos Therapeutics
Financial Information
Market Cap
Revenues $14.7 mil (last 12 months)
Net Income $-8.4 mil (last 12 months)
IPO Profile
Symbol VVOS
Exchange NASDAQ
Shares (millions): 3.5
Price range $6.00 - $6.00
Est. $ Volume $21.0 mil
Manager / Joint Managers Roth Capital Partners
CO-Managers Craig-Hallum/ National Securities
Expected To Trade: 12/11/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change